HEALTH & SCIENCE FEED

Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook | Wegovy Approved for Liver Disease: A Breakthrough for MASH Treatment | Pentagon Halts Key Hurricane Satellite Data, Raising Forecast Concerns | Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook | Wegovy Approved for Liver Disease: A Breakthrough for MASH Treatment | Pentagon Halts Key Hurricane Satellite Data, Raising Forecast Concerns

Health & Science / Pharmaceuticals

Novo Nordisk's Wegovy Sales Jump, Boosting 2026 Outlook

Novo Nordisk (NVO) has revised its full-year guidance for 2026 following stronger-than-expected sales of its Wegovy weight-loss pill. The company's stock experienced a notable increase as the market responded positively to the news.

Image via CNBC

May 06, 2026 11:00 Wegovy pill sales smash forecasts, sending Novo Nordisk stock 7% higher

Health & Science / Pharmaceuticals

Wegovy Approved for Liver Disease: A Breakthrough for MASH Treatment

Aug 18, 2025 12:03 Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

Health & Science / Weather

Pentagon Halts Key Hurricane Satellite Data, Raising Forecast Concerns

Jun 27, 2025 18:02 Pentagon Sends Hurricane Forecasters Scrambling After Suddenly Announcing Shutdown of Key Satellites

Pharmaceuticals Weather